From COVID-19 to COVI-Flu: A Burgeoning Pandemic

1 - 20

oryan's Recent Documents

sh͕ Ed͕ E͕ Z͕ Θ t
sh͕ Ed͕ E͕ Z͕ Θ t

6DIDUL :HVW ,ŝƐƚŽƌLJ • WĞƚĞƌ ĂŶĚ EĂŶĐLJ >ĂŶŐ • ĂƚƚůĞ ƚŽ ŶƚĞůŽƉĞ ± /ŶƐƉŝƌĂƚŝŽŶ • EĂŶĐLJ ĨŽƌ ĞĚƵĐĂƚŝŽŶ ± ^ĐŚŽŽů Őƌ

published 0K
COVID-19 Team Wellness Assessment (Game)
COVID-19 Team Wellness Assessment (Game)

Coach: Age Group: Game or Practice Date: Coach Asst Coach/Team Mgr Player Name Player Name Player Name Player Name Player Name Player Name Player Name Player Name Player Name Player Name Player

published 0K
HelicobacterpyloriCagA:TheBacterialOncoprotein14PaoloRuggiero
...
HelicobacterpyloriCagA:TheBacterialOncoprotein14PaoloRuggiero ...

AbstractHelicobacterpyloriinfectsthehumanstomach,causingatrophicgastritis,peptic #SpringerScience+BusinessMediaB.V.2018 KeywordsHelicobacterpylori

published 0K
Services, 7estern Illinois 5niversity.
Services, 7estern Illinois 5niversity.

Promoting Inquiry-Based Science Instruction The 6alidation of the Science Teacher Inquiry Rubric (STIR) Alec M. Bodzin Lehigh 5niversity Karen M. Beerer 1uakertown Community School District

published 0K
MICROCART 2014Xilinx Tools (XPS, XSDK, and XISE) Setup and Walkthrough
MICROCART 2014Xilinx Tools (XPS, XSDK, and XISE) Setup and Walkthrough

Using a MicroSD Card to program the Zybo Board ��IntroductionPageIntroductionWelcome to the ultimate Xilinx ToolsHowTo guide! This guide should provide you with all the necessary knowled

published 0K
Plant Guide
Plant Guide

Poa bulbosaPlant Symbol = POBUContributed by: USDA NRCS Plant Materials Dave Skinner, Pullman PMC Alternate Names Winter bluegrass CulturalBulbous bluegrass is currently considered to be a weedy spe

published 0K
Horizontal multistage pump with electronic system HIGH-FLOW  Descripti
Horizontal multistage pump with electronic system HIGH-FLOW Descripti

Up/Down technology for submersed, surface orunderground installationAutomatic system of water supply; dry-running protectionAntiblocking system every 72 hours of pump inactivityProtection rating IP68

published 1K
Views and  references
Views and references

Technical details Designs Models and dimensions Awards, standardsand certificates Accessories and other items Technical details Views and references Technical details Designs Models and dimensions

published 1K

Document on Subject : "From COVID-19 to COVI-Flu: A Burgeoning Pandemic"— Transcript:

1 Page 9 From COVID-19 to COVI-Flu: A Burg
Page 9 From COVID-19 to COVI-Flu: A Burgeoning Pandemic Yan Leyfman 1 , Timothy K. Erick 1 , Pushpa Sharma 1,2 1 WACEM-ACAIM Joint Global COVID-19 Taskforce— Immunology Division, USA 2 Department of Anaesthesiology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA Citation: Yan Leyfman; From COVID-19 to COVI-Flu: A Burgeoning Pandemic; COVID Vaccines 2020 ; August 31, 2020 | Paris, France Webinar on COVID-19 Vaccination | August 31, 2020 | Paris, France Abstract: Coronavirus disease 2019 (COVID-19), a respiratory ill - ness caused by the novel betacoronavirus SARS-CoV-2, has rapidly caused a global pandemic. This viral infec - tion has broad symptomatic presentations, ranging from asymptomatic to fatal. Studies have demonstrated that patients with severe symptoms and elevated pro-inflam - matory (IL-1β, IL-6, IFN-, and TNF-) and lower anti-in - flammatory cytokine levels (IL-10) tend to possess a poor prognosis. Based on the available evidence, we proposed a mechanism by which SARS-CoV-2 infection causes systemic organ damage through IL-6-mediated inflam - mation. Elevated IL-6 fuels a cytokine release syndrome and hypoxia, resulting in vast systemic injury, multi-or - gan damage, and eventually organ failure. Additionally, we propose a potential synergism between influenza virus and SARS-CoV-2, which we termed “COVI-Flu.” Under our model, simultaneous infection with both viruses will cause a further increase in IL-6 production, which will yield more widespread systemic inflammation and injury than infection with either virus alone. Current - ly, there are no available safe and effective therapeutic interventions against SARS-CoV-2 or COVI-Flu. Based on the similarities between the disease mechanisms of SARS-CoV-2 and influenza virus, we proposed the idea of a combination therapy that can control the systemic inflammation induced by both viruses. One promising approach is a cellular therapy that has yielded promising preliminary efficacy in COVID-19 patients. Looking for - ward, we see combinational therapies being used that can better thwart the virus’s heterogeneity and mutational adaptations. In anticipation of the impending COVI-Flu pandemic Biography: Yan Leyfman has contributed to the development of sev - eral anti-cancer therapies that have recently entered clin - ical trials and his successes have been recognized by such prestigious organizations as the Barry M. Goldwater Re - search Foundation, Sigma Xi, New York Times, USA To - day, National Society of Collegiate Scholars, and Harvard Medical School. He has been recognized as one of the top medical student researchers in oncology nationally by the American Society of Hematology and American Society of Clinical Oncology and locally by the Pennsylvania Society of Oncology & Hematology and the American College of Physicians. During the COVID-19 pandemic, he was re - cruited to join the Global COVID-19 Taskforce to serve as a Special Advisor for Immunology, Oncology and Cellular Therapeutics and was made Director of the Immunology Group, which produced a cohesive mechanism of action for SARS-CoV-2, a new prognostic assay to predict patient outcomes, and the first synergistic paradigm between the flu and SARS-CoV-2, termed “COVI-Flu” along with therapeutic interventions for both. Within days of publi - cation ahead of print as the upcoming cover article in the journal, Shock, this manuscript received over 32 million views and was amongst the top five COVID-19 articles worldwide according to QxMD. Publication of speakers: 1. de Brito, R. C., N. Lucena-Silva, L. C. Torres, C. F. Luna, J. B. Correia, and G. A. da Silva. 2016. The balance between the serum levels of IL-6 and IL-10 cytokines discriminates mild and severe acute pneu - monia. BMC Pulm Med 16: 170. Journal of Vaccines and Vaccination Abstract J Vaccines and Vaccination 2020 Volume and Issue: S(3)